ClinicalTrials.gg
RecruitingNCT06886347Updated Mar 20, 2025

Metastatic Nasopharyngeal Carcinoma

A Phase 1 interventional study of Penplimab Injection and Antitinib Hydrochloride Capsules in Metastatic Nasopharyngeal Carcinoma, sponsored by Chen Xiaozhong. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Chen Xiaozhong · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing gemcitabine in Nasopharyngeal Carcinoma — 11 open to participants now, 15 under way, 7 of them phase 3. Gemcitabine · Nasopharyngeal Carcinoma.

Planned enrollment
21st of 26
47 · median 152
Started
2023
with 2 others
Phase 1
3 of 26
1 open now
Primary completion
2026-04
later than 6 of 14 live
Registered
18th of 26
by date
Lead sponsor
1 of 26
Chen Xiaozhong

Among the 26 studies testing gemcitabine in Nasopharyngeal Carcinoma, this one is the 21st largest by planned enrollment, is one of 3 that started in 2023, is one of 3 in phase 1, reaches primary completion later than 6 of the 14 other live ones, and was the 18th registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

11 of the 26 studies testing gemcitabine in Nasopharyngeal Carcinoma are open now, in 9 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing gemcitabine in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

To evaluaate the efficacy and safety of the regimen incuding Penpulimab, Gemcitabine and Anlotinib in the treatment of metastatic nasopharyngeal carcinoma. Using Progression-Free-Survival as the primary endpoint.

03

Conditions studied

  • Metastatic Nasopharyngeal Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participants voluntarily signed an form.
  2. Age of ≥ 18 years and ≤ 75 years at the time of enrollment.
  3. (ECOG) performance status of 0 or 1.
  4. xpected survival of ≥ 3 months.
  5. or cytologically confirmed diagnosis of stage IVb NPC (AJCC 8th).
  6. NPC patients who have not recieved the platinumbased chemotherapy.
  7. At least one measurable tumor lesion per 1.1 criteria.
  8. Adequate organ function.
  9. Female participants of must agree to use (such as intrauterine device, contraceptive pill, or condom) during the study and for 6 months after the end of the study; must have a negative serum pregnancy test within 7 days before study entry and must not be lactating. Male participants must agree to use contraception during the study and for 6 months after the end of the study.
  10. The subjects are willing and able to comply with the visit schedule, treatment plan, laboratory examination, and other requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. ubjects have had another within 3 years before the first dose, except nasopharyngeal carcinoma. Subjects with other malignancies that have been cured by local therapy such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervix or breast carcinoma in situ are not excluded.
  2. Participation in treatment with an drug or use of an investigational device within 4 weeks before first study dosing.
  3. Palliative local treatment was performed for non target lesions within 2 weeks before the first administration; Received nonspecific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc., excluding IL-11 for the treatment of thrombocytopenia) within 2 weeks before the first administration; Received Chinese herbal medicine or Chinese patent medicine with anti-tumor indications within 1 week before the first administration.
  4. Progression during or within 6 months after receiving systemic treatment for locally advanced disease (including induction therapy, concurrent radiotherapy, therapy) (excluding oral single agent chemotherapy maintenance).
  5. Patients with local recurrence and distant after radical treatment for locally advanced disease.
  6. Patients with recurrent nasopharyngeal lesions after radiotherapy and who have received secondary radiotherapy.
  7. Have previously received immunotherapy, including , immune checkpoint agonists , immune cell therapy, and other treatments against tumor immune mechanism.
  8. Previously received anti angiogenic therapy.
  9. According to the judgment of the investigator, there are subjects with concomitant diseases that seriously endanger the safety of subjects or affect the completion of the study, or subjects who believe that there are other reasons that are not suitable for enrollment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Experimental: The dosage of penplimab injection is 200 mg per session, administered on the first day of each cycle, Q3W

    Drug: Penplimab Injection · Drug: Antitinib Hydrochloride Capsules · Drug: Gemcitabine

Interventions

  • DrugPenplimab Injection

    Penplimab Injection: Intravenous infusion of Penplimab 200 mg Q3W, with a 3-week treatment cycle. Anlotinib Hydrochloride Capsules: 10 mg, taken orally on an empty stomach before breakfast once a day (the daily medication time should be the same as much as possible), delivered in warm water, continuously used for 2 weeks and stopped for 1 week, with a treatment cycle of 3 weeks. Gemcitabine injection: Intravenous infusion of 1000mg/m2, administered on the 1st and 8th days of each cycle, 3 weeks per cycle for 4-6 cycles.

  • DrugAntitinib Hydrochloride Capsules

    10 mg, taken orally on an empty stomach before breakfast once a day (the daily medication time should be the same as much as possible), delivered in warm water, continuously used for 2 weeks and stopped for 1 week, with a treatment cycle of 3 weeks.

  • Intravenous infusion of 1000mg/m2, administered on the 1st and 8th days of each cycle, 3 weeks per cycle for 4-6 cycles.

06

What researchers measure

Primary outcomes

  1. PFS

    PFS defined as the time from the first dose until the first documented progressive disease (PD) or death from any cause.

    Time frame: Baseline up to 2 years

Secondary outcomes

  1. Objective Response Rate(ORR)

    Percentage of subjects achieving complete response (CR) and partial response (PR)

    Time frame: Baseline up to 2 years

  2. Disease Control Rate (DCR)

    Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD)

    Time frame: Baseline up to 2 years

  3. Overall survival (OS)

    OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up

    Time frame: Baseline up to 2 years

  4. Time to Response (TTR)

    TTR defined as the time from randomization to the first recorded CR or PR

    Time frame: Baseline up to 2 years

  5. Duration of Response (DOR)

    DOR defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first.

    Time frame: Baseline up to 2 years

  6. PD-L1 expression

    Evaluating the correlation between PD-L1 expression and efficacy in tumor tissue samples.

    Time frame: Tumor tissue samples must be provided to the research center prior to initial administration

  7. Blood EBV level

    Evaluate the correlation between the copy number of EBV DNA in the blood of subjects and their efficacy.

    Time frame: Baseline up to 2 years

  8. Evaluate the health-related quality of life (HRQoL) of subjects

    Evaluate the health-related quality of life (HRQoL) of subjects using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire scale。The minimum values is 1,the maximum values is 4,and whether higher scores mean a worse outcome.

    Time frame: Baseline up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Apr 2026, 32 months after the start.

Of 28 phase 1 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 75. This study's planned 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Mar 20, 2025
StartActual
Jul 7, 2023
Primary completionEst.
Apr 1, 2026
CompletionEst.
Apr 1, 2026
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06886347
Lead sponsor
Chen Xiaozhong
Responsible party
Chen Xiaozhong (chief physicians, Zhejiang Cancer Hospital) — Sponsor-investigator
First posted
Mar 20, 2025
Start date
Jul 7, 2023
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Mar 20, 2025

Study contacts

Xiaozhong Chen, Doctor
Contact
chenxz@zjcc.org.cn
0571-88128202

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion